Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Short Interest Up 12.7% in July

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 14,560,000 shares, an increase of 12.7% from the June 30th total of 12,920,000 shares. Based on an average trading volume of 950,200 shares, the short-interest ratio is currently 15.3 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Lineage Cell Therapeutics in a report on Monday, May 6th.

Lineage Cell Therapeutics Stock Performance

NYSEAMERICAN:LCTX remained flat at $1.02 on Monday. 524,303 shares of the company’s stock were exchanged, compared to its average volume of 945,123. Lineage Cell Therapeutics has a 52-week low of $0.84 and a 52-week high of $1.61.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). The firm had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.22 million. Lineage Cell Therapeutics had a negative net margin of 295.59% and a negative return on equity of 34.92%. Research analysts predict that Lineage Cell Therapeutics will post -0.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Large investors have recently made changes to their positions in the company. Fifth Third Wealth Advisors LLC bought a new position in Lineage Cell Therapeutics in the first quarter valued at approximately $30,000. SG Americas Securities LLC boosted its position in shares of Lineage Cell Therapeutics by 61.6% in the 4th quarter. SG Americas Securities LLC now owns 30,889 shares of the company’s stock worth $34,000 after purchasing an additional 11,779 shares during the last quarter. DCF Advisers LLC grew its stake in shares of Lineage Cell Therapeutics by 14.5% during the fourth quarter. DCF Advisers LLC now owns 94,751 shares of the company’s stock worth $103,000 after purchasing an additional 12,000 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Lineage Cell Therapeutics by 77.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 161,314 shares of the company’s stock valued at $239,000 after purchasing an additional 70,418 shares during the last quarter. Finally, Comerica Bank lifted its stake in Lineage Cell Therapeutics by 84,745.8% in the first quarter. Comerica Bank now owns 250,295 shares of the company’s stock valued at $370,000 after buying an additional 250,000 shares during the period. Institutional investors and hedge funds own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.